POSLUMA®

Hold Company

BLUE EARTH

Learn More

Dosage and Administration

SOLUTION;INTRAVENOUS

Specification

25ML (8-158mCi/ML)

Indication

Posluma® is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.

Use

Instructions for Use

API

FLOTUFOLASTAT F-18

API Structure

We Supply

FLOTUFOLASTAT F-18

Drug Patent

Patent No	Expiration Date
11413360	11/22/2038
12036290	11/27/2041

API Patent

Patent No	Expiration Date
11413360	11/22/2038

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.